ORIGINAL RESEARCH article

Front. Med.

Sec. Infectious Diseases: Pathogenesis and Therapy

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1575411

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in HIV Treatment: A Real-World Single-Center Study in China

Provisionally accepted
Aixin LiAixin Li1Letian LiuLetian Liu1Hongwei ZhangHongwei Zhang1Xi WangXi Wang1Zaicun LiZaicun Li1An LiuAn Liu1Lili DaiLili Dai1Jingji ZhangJingji Zhang1Yue GaoYue Gao1Jiangzhu YeJiangzhu Ye1Jianwei LiJianwei Li1Lijun SunLijun Sun1,2*
  • 1Beijing Youan Hospital, Capital Medical University, Beijing, China
  • 2Chinese Association of STD and AIDS Prevention and Control, Care and Treatment Committee, Beijing, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

The single-tablet regimen Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) has been included in international guidelines and recommendations. It and was approved by China's National Medical Products Administration (NMPA) in early 2021 for adult human immunodeficiency virus (HIV)-1 infections. This study presents real-world results of a retrospective analysis of patients who initiated DOR/3TC/TDF at a single Chinese HIV center in China.This retrospective analysis was carried out on patients who received DOR/3TC/TDF (initial or switch) at the outpatient clinic of the Infection Center in Beijing Youan Hospital in China. We meticulously collected the pPatients' baseline characteristics, the reasons for their switching to DOR/3TC/TDF, along with the preliminary clinical, laboratory -based efficacy, safety, and tolerability data, were collected. All evaluations were in strict accordance with the protocols of our center.The statistical analysis was mainly descriptive, aiming to assess the changes in laboratory parameters from the baseline to the data -collection deadline, which was

Keywords: HIV, Doravirine, DOR/3TC/TDF, Real-world, antiretroviral therapy

Received: 12 Feb 2025; Accepted: 15 May 2025.

Copyright: © 2025 Li, Liu, Zhang, Wang, Li, Liu, Dai, Zhang, Gao, Ye, Li and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lijun Sun, Beijing Youan Hospital, Capital Medical University, Beijing, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material